During the afternoon session, Natera moved 9.89%, compared to -0.028% for the S&P 500.
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is now trading -26.63% away from its average analyst target price of $72.71 per share. The 13 analysts following the stock have set target prices ranging from $28.0 to $97.0, and on average give Natera a rating of buy.
Over the last year, NTRA shares have gone down by -24.56%, which represents a difference of -15.07% when compared to the S&P 500. The stock's 52 week high is $63.65 per share and its 52 week low is $26.1. With its gross margins declining an average -7.74% over the last four years, Natera may not have a strong enough business to reverse this trend.
Date Reported | Revenue (k) | Cost of Revenue (k) | Gross Margin | YoY Growth |
---|---|---|---|---|
2021-12-31 | $617,025 | $512,490 | 16.94% | -5.36% |
2020-12-31 | $370,075 | $303,827 | 17.9% | -56.82% |
2019-12-31 | $306,023 | $209,368 | 41.45% | 11.85% |
2018-12-31 | $247,190 | $315,297 | 37.06% | 11.63% |
2017-12-31 | $210,939 | $140,910 | 33.2% | n/a |